These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10476928)

  • 21. [Treatment of acute hepatitis C].
    García Compeán D
    Rev Gastroenterol Mex; 2002 Oct; 67 Suppl 2():S61-6. PubMed ID: 12712857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic effects of orally administered interferons and interleukin-2.
    Fleischmann WR; Koren S
    J Interferon Cytokine Res; 1999 Aug; 19(8):829-39. PubMed ID: 10476926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of low-dose interferon therapy for treating chronic hepatitis C patients who cannot tolerate standard treatment].
    Cao ZH; Liu YL; Zheng YH; Ji SD; Wang JL; Liao JH; Zhang CY; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):20-4. PubMed ID: 22464701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative interferons and immunomodulators in the treatment of hepatitis C.
    Alao H; Jake Liang T
    Liver Int; 2014 Feb; 34 Suppl 1():133-8. PubMed ID: 24373090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
    Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
    Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model.
    Bekkering FC; Stalgis C; McHutchison JG; Brouwer JT; Perelson AS
    Hepatology; 2001 Feb; 33(2):419-23. PubMed ID: 11172344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of peripheral leukocyte counts in mice by oral administration of interferons.
    Fleischmann WR; Fields EE; Wang JL; Hughes TK; Stanton GJ
    Proc Soc Exp Biol Med; 1991 Sep; 197(4):424-30. PubMed ID: 1714606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of Chinese herbal medicine Xin-kang oral liquid on interferon-induction and its antiviral activity in coxsackievirus B3 infected mice].
    Wan SJ; Li JN; Zhao H; Wang LX; Huang XZ; Zhu Y; Chen HS
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Mar; 19(1):77-9. PubMed ID: 16201482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
    Meager A; Das RG
    J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferon].
    Tamori A; Kawada N
    Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of chronic hepatitis B].
    Asselah T; Lada O; Boyer N; Martinot M; Marcellin P
    Gastroenterol Clin Biol; 2008; 32(8-9):749-68. PubMed ID: 18775613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of chronic hepatitis with interferon in children with kidney diseases].
    Szczepańska M; Tobis A; Schneiberg B; Szprynger K; Kobos E; Morawiec-Knysak A
    Pol Merkur Lekarski; 2005 Jan; 18(103):22-8. PubMed ID: 15859541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization.
    Poreaux C; Bronowicki JP; Debouverie M; Schmutz JL; Waton J; Barbaud A
    Clin Exp Allergy; 2014; 44(5):756-64. PubMed ID: 24128045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon, cortisone, and antivirals in the treatment of chronic viral hepatitis: a review of 30 years of therapy.
    Malaguarnera M; Restuccia S; Motta M; Ruello P; Trovato BA; Pistone G
    Pharmacotherapy; 1997; 17(5):998-1005. PubMed ID: 9324188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma.
    Liu G; Zhai Q; Schaffner DJ; Wu A; Yohannes A; Robinson TM; Maland M; Wells J; Voss TG; Bailey C; Alibek K
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):201-6. PubMed ID: 15039095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral use of interferon therapy in cervical human papillomavirus infection.
    Palomba M; Melis GB
    Clin Ter; 2000; 151(1 Suppl 1):59-61. PubMed ID: 10876967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oromucosal interferon therapy: relationship between antiviral activity and viral load.
    Schellekens H; Geelen G; Meritet JF; Maury C; Tovey MG
    J Interferon Cytokine Res; 2001 Aug; 21(8):575-81. PubMed ID: 11559435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential for orally administered type 1 interferons.
    Beilharz MW
    Pharm Sci Technol Today; 2000 Jun; 3(6):193-197. PubMed ID: 10840389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.